[1] Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci, 2006; 3, 47-52. http://d.old.wanfangdata.com.cn/OAPaper/oai_doaj-articles_cca4fe43e3264b66c253643f0f7650bc
[2] Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. The guideline of prevention and treatment for hepatitis C:a 2015 update. Chin J Hepatol, 2015; 23, 906-23. (In Chinese) http://en.cnki.com.cn/Article_en/CJFDTotal-CRBX201101003.htm
[3] Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology, 2001; 34, 809-16. doi:  10.1053/jhep.2001.27831
[4] El-Serag HB, Rudolph KL. HepatocelIular carcinoma:epidemiology and molecular carcinogenesis. Gastroenterology, 2007; 132, 2557-76. doi:  10.1053/j.gastro.2007.04.061
[5] European Association for Study of Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol, 2015; 63, 199-236. doi:  10.1016/j.jhep.2015.03.025
[6] John-Baptiste AA, Tomlinson G, Hsu PC, et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol, 2009; 104, 2439-48. doi:  10.1038/ajg.2009.346
[7] Chen XY, Shang J, Yang RF, et al. High sustained virological response to optimized therapy for refractory chronic hepatitis C treatment-naive patients:a multicenter randomized study. Chin J Hepatol, 2015; 23, 412-7. (In Chinese)
[8] Qin QQ, Guo W, Wang LY, et al. Epidemiological characteristics of hepatitis C in China, 1997-2011. Chin J Epidemiol, 2013; 34, 548-51. (In Chinese) http://d.old.wanfangdata.com.cn/Periodical/xdyfyx201507008
[9] Chen FF, Wang LY, Qin QQ, et al. Re-reporting and diagnosis of hepatitis C in China. Disease Surveillance, 2014; 29, 578-82. (In Chinese) http://d.old.wanfangdata.com.cn/Periodical/jbjc201407017